CD19 and lymphoma: However, unlike the favorable results in B-cell lymphocytic leukemia, the clinical benefit of anti-CD19 CAR (CD19 CAR)-T cell therapy in lymphoma is limited, partially due to the development of an immunosuppressive tumor microenvironment (3, 4).